Pipeline

R&D

Status of Product Development

Progress with regenerative cell medicines currently in development

                     
Cell drug Indication Research Nonclinical PHASE1 PHASE2 PHASE3
SB623 Traumatic brain injury(chronic) US
       
JP
       
Ischemic stroke (chronic) US
       
Hemorrhagic stroke (chronic)       1
Dry age-related macular degeneration
       
Retinitis pigmentosa
       
Parkinson`s disease
       
Spinal cord injury
       
Alzheimer`s disease
       
SB618 Peripheral nerve damage, etc
       
SB308 Muscle dystrophy, etc
       
MSC1 Cancer
       
MSC2 Inflammatory disease
       
※1Clinical trials of Hemorrhagic stroke are expected to begin in Phase 2 or Phase 3. Expanded Access Program